Track topics on Twitter Track topics that are important to you
Heptares Therapeutics and PeptiDream established a strategic collaboration to discover, develop and commercialize therapeutics targeting a jointly selected, undisclosed G protein-coupled receptor (GPCR) implicated in inflammatory diseases. No financial details have been disclosed. U.K.-based Heptares, which is a wholly owned subsidiary of Japan’s Sosei Group, will apply its StaR® platform to generate 3D target structure information. Japanese firm PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) to identify macrocyclic/constrained peptides against the GPCR target, and to optimize peptides and/or small molecules for further development. The partners will combine their respective expertise and resources to advance candidates into the clinic, and jointly conduct and share the costs of discovery and development. Any resulting products will also be co-owned. Malcolm Weir, CEO at Heptares and chief R&D officer at Sosei, said, "In bringing together Heptares and PeptiDream technologies under this collaboration, we hope to create a ...NEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...